1. 1Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil;
2. 2Laboratory of Immunothrombosis, Department of Biochemistry, Federal University of Juiz de Fora (UFJF), Juiz de Fora, Brazil;
3. 3Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation, Rio de Janeiro, Brazil;
4. 4Laboratory on Thymus Research, and
5. 5National Institute for Science and Technology on Neuroimmunomodulation, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, Brazil;
6. 6Immunology and inflammation (IMPPG), Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil;
7. 7Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil;
8. 8Paulo Niemeyer State Brain Institute, Rio de Janeiro, Brazil;
9. 9National Institute of Infectious Disease Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil;
10. 10D’Or institute for Research and Education, Rio de Janeiro, Brazil;
11. 11Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil;
12. 12Laboratory of Inflammation and Biomarkers, Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Salvador, Brazil;
13. 13Hospital Israelita Albert Einstein, São Paulo, Brazil; and
14. 14Institute of Medical Biochemistry Leopoldo de Meis (IBqM), Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil